Plain-English translation of NCT07235527 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Age Related Macular Degeneration research guide →This trial tested Yesafili, a biosimilar version of a medication already used to treat wet age-related macular degeneration (a serious eye condition affecting older adults). Researchers examined how well this new formulation worked in real-world clinical practice by tracking patients' eye health and vision over time using standard eye exams and imaging tests.
Wet age-related macular degeneration can cause significant vision loss, and patients need reliable treatment options. This medication has been proven effective, but testing a biosimilar version—which is a more affordable alternative—helps ensure it works just as well for patients who need it.
Participants received eye injections of the medication as part of their regular eye care. During routine clinic visits, doctors examined participants' eyes and took imaging scans to monitor how the treatment was working and track any changes in their vision and eye health over time.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
Turkey (Türkiye)
Sponsor
Saglik Bilimleri Universitesi
Enrollment target
~54 participants
Started
November 2025
Primary completion
August 2026
Age range
45 Years – 90 Years
Last updated on clinicaltrials.gov in September 2026.